MNMichael NinburgSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019WHA / Community Perspective on the Need for Simplification- Michael NinburgView Slideset
PEPhilippa EasterbrookBSc (Hons), MD, MPH, DTM&H, FRCPSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019WHO / Perspective on the Simplification Strategies- Philippa Easterbrook, MD, FRCP, MPH, DTM&HView Slideset
JFJordan FeldMD, MPHSlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2019Introduction of Simplification- Jordan Feld, MD, MPHView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Levofloxacin Target Attainment Analysis in MDR-TB Patients: Time is Ripe for Proactive TDM - Mathieu BolhuisView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Drug Effect of Clofazimine on Persistent Mycobacteria Explain an Unexpected Increase of Bacterial Load in Patients - Alan FarajView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment Analysis - Charles PeloquinView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019PK-PD of Isoniazid Given at Different Doses Among Patients with MDR-TB with INH Resistance Mediated by inhA Mutations: Modeling Results from ACTG A5312 - Kamunkhwala GausiView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Pharmacokinetic-Pharmacodynamic Analysis in TB Drug Development and the Role of the WHO - Ernesto JaramilloView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Can Longitudinal PKPD Biomarkers be used to Forecast Treatment Outcome Instead of M2 Conversion? A Population Pharmacokinetic-Pharmacodynamic Analysis in Drug Sensitive Pulmonary Tuberculosis - Frank KloproggeView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Ethionamide Population Pharmacokinetic Model and Monte Carlo Simulation in Patients with Multidrug-Resistant Tuberculosis - Charles PeloquinView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Exposures to First-Line Drugs in African and Indian Children with Drug-Susceptible Tuberculosis using Novel Fixed-Dose-Combination Tablets at WHO Dosing Recommendation in the SHINE Trial - Chishala ChabalaView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019Co-Administration of Pretomanid with Rifampin or Rifabutin Among Patients with Pulmonary TB: Interim PK Results from “Assessing Pretomanid for Tuberculosis” (APT) Trial - Elisa IgnatiusView Slideset
